Pomerantz Law Firm's Investigation into Immix Biopharma's Alleged Misconduct Raises Investor Concerns
On August 13, 2026, the Pomerantz Law Firm announced they are initiating an investigation on behalf of investors associated with Immix Biopharma, Inc. (NASDAQ: IMMX). This inquiry comes at a crucial moment as concerns abound about the company's business practices and the integrity of its leadership. Investors seeking to get more information can reach out to Danielle Peyton via the provided contact details.
The investigation focuses on allegations surrounding Immix and its senior officials possibly being involved in securities fraud or other illegitimate business activities. This team of legal experts aims to uncover the truth behind these claims as the firm is known for advocating for victims of corporate misconduct.
A major trigger for the investigation was the controversial firing of Richard Graydon, who had only recently been appointed as the Chief Medical Officer. On March 30, 2026, Immix made a public announcement about Graydon stepping into this critical role. However, just a few months later, on July 20, 2026, the company disclosed that he was terminated effective July 17 for reasons stated to be unrelated to his performance.
The situation took a darker turn when media reports began surfacing regarding Graydon’s true identity, revealing that he had previously gone by the name Ronald L. Fischer. Fischer was a fugitive who had eluded capture for over two decades following a rape trial back in 2005. His arrest in July 2026, resulting from a significant law enforcement operation, sent shockwaves throughout the financial community, inducing a sharp decline in Immix's stock price. On the announcement day of his real identity, shares plummeted by $1.45 or approximately 14.15%, closing the day at $8.80.
Pomerantz LLP, with a rich history and a reputation as a leading firm in corporate, securities, and antitrust class actions, was founded by the renowned Abraham L. Pomerantz, known for his pivotal role in the establishment of securities class actions. The firm continues its legacy of protecting investors’ rights and holding corporations accountable for misconduct.
For investors who may have faced losses during this tumultuous period, this investigation represents a potential pathway to justice. By consolidating in numbers, they can challenge corporate fraud and mismanagement, a pursuit that Pomerantz is well-equipped to undertake. Stakeholders are urged to consider joining the class action as they look for ways to mitigate the impact of this unsettling development.
Pomerantz's history of securing substantial damages on behalf of its clients reassures investors that they are not alone in navigating the complexities of corporate legal battles. For more details on how to participate, potential class members can refer to the official communication channels from Pomerantz, which are readily available for inquiry.
In conclusion, the unfolding narrative within Immix Biopharma highlights a vital aspect of the investment landscape—due diligence and corporate transparency. Pomerantz Law Firm’s involvement serves as a reminder that investors have channels to seek justice when faced with potentially devastating revelations concerning the companies in which they have placed their trust.
The investigation focuses on allegations surrounding Immix and its senior officials possibly being involved in securities fraud or other illegitimate business activities. This team of legal experts aims to uncover the truth behind these claims as the firm is known for advocating for victims of corporate misconduct.
A major trigger for the investigation was the controversial firing of Richard Graydon, who had only recently been appointed as the Chief Medical Officer. On March 30, 2026, Immix made a public announcement about Graydon stepping into this critical role. However, just a few months later, on July 20, 2026, the company disclosed that he was terminated effective July 17 for reasons stated to be unrelated to his performance.
The situation took a darker turn when media reports began surfacing regarding Graydon’s true identity, revealing that he had previously gone by the name Ronald L. Fischer. Fischer was a fugitive who had eluded capture for over two decades following a rape trial back in 2005. His arrest in July 2026, resulting from a significant law enforcement operation, sent shockwaves throughout the financial community, inducing a sharp decline in Immix's stock price. On the announcement day of his real identity, shares plummeted by $1.45 or approximately 14.15%, closing the day at $8.80.
Pomerantz LLP, with a rich history and a reputation as a leading firm in corporate, securities, and antitrust class actions, was founded by the renowned Abraham L. Pomerantz, known for his pivotal role in the establishment of securities class actions. The firm continues its legacy of protecting investors’ rights and holding corporations accountable for misconduct.
For investors who may have faced losses during this tumultuous period, this investigation represents a potential pathway to justice. By consolidating in numbers, they can challenge corporate fraud and mismanagement, a pursuit that Pomerantz is well-equipped to undertake. Stakeholders are urged to consider joining the class action as they look for ways to mitigate the impact of this unsettling development.
Pomerantz's history of securing substantial damages on behalf of its clients reassures investors that they are not alone in navigating the complexities of corporate legal battles. For more details on how to participate, potential class members can refer to the official communication channels from Pomerantz, which are readily available for inquiry.
In conclusion, the unfolding narrative within Immix Biopharma highlights a vital aspect of the investment landscape—due diligence and corporate transparency. Pomerantz Law Firm’s involvement serves as a reminder that investors have channels to seek justice when faced with potentially devastating revelations concerning the companies in which they have placed their trust.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.